PROX1 gene variant is associated with fasting glucose change after antihypertensive treatment

Pharmacotherapy

Volumn 34, Issue 2, 2014, Pages 123-130

  Gong, Yan ^a   McDonough, Caitrin W ^a   Beitelshees, Amber L ^b   Karnes, Jason H ^c   O'Connell, Jeffrey R ^b   Turner, Stephen T ^d   Chapman, Arlene B ^e   Gums, John G ^a,f   Bailey, Kent R ^d   Boerwinkle, Eric ^g   Johnson, Julie A ^a,f   Cooper DeHoff, Rhonda M ^a,f  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MAYO CLINIC ROCHESTER   (United States)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^g UNIVERSITY OF TEXAS   (United States)

Author keywords

Adverse metabolic effects; Antihypertensives; Atenolol; Dysglycemia; Hydrochlorothiazide; Hypertension; Pharmacogenomics

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATENOLOL; CYTOSINE; GLUCOSE; HYDROCHLOROTHIAZIDE; INSULIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; GLUCOSE BLOOD LEVEL; HOMEODOMAIN PROTEIN; PROSPERO-RELATED HOMEOBOX 1 PROTEIN; TUMOR SUPPRESSOR PROTEIN;

5' UNTRANSLATED REGION; ADULT; AGE DISTRIBUTION; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY MASS; CAUCASIAN; CONTROLLED STUDY; DIABETES MELLITUS; DRUG DOSE TITRATION; FEMALE; FOLLOW UP; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; PHARMACOGENETICS; PROX1 GENE; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; DIET RESTRICTION; DRUG COMBINATION; DRUG EFFECTS; GENETICS; MIDDLE AGED; RISK FACTOR; STATISTICAL MODEL;

ADRENERGIC BETA-ANTAGONISTS; ADULT; ANTIHYPERTENSIVE AGENTS; ATENOLOL; BLOOD GLUCOSE; DRUG THERAPY, COMBINATION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FASTING; FEMALE; HOMEODOMAIN PROTEINS; HUMANS; HYDROCHLOROTHIAZIDE; HYPERGLYCEMIA; HYPERTENSION; LINEAR MODELS; MALE; MIDDLE AGED; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 84898023511     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/phar.1355     Document Type: Article

References (27)

1. Go AS, Mozaffarian D, Roger VL, et al. Subcommittee obotAHASCaSS. Heart disease and stroke statistics-2013 update: a report from the american heart association. Circulation 2013;127:e6-245.
2. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the jnc 7 report. JAMA 2003;289: 2560-72.
3. Lithell HO. Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism. Diabetes Care 1991;14: 203-9.
4. Cooper-DeHoff RM, Wen S, Beitelshees AL, et al. Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications. Hypertension 2010;55: 61-8.
5. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007;369: 201-7.
6. Messerli FH, Bangalore S, Julius S. Risk/benefit assessment of beta-blockers and diuretics precludes their use for first-line therapy in hypertension. Circulation 2008;117: 2706-15; discussion 2715.
7. Barzilay JI, Davis BR, Cutler JA, et al. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Arch Intern Med 2006;166: 2191-201.
8. Smith SM, Gong Y, Turner ST, et al. Blood pressure responses and metabolic effects of hydrochlorothiazide and atenolol. Am J Hypertens 2012;25: 359-65.
9. Maitland-van der Zee AH, Turner ST, Schwartz GL, Chapman AB, Klungel OH, Boerwinkle E. Demographic, environmental, and genetic predictors of metabolic side effects of hydrochlorothiazide treatment in hypertensive subjects. Am J Hypertens 2005;18: 1077-83.
10. Karnes JH, McDonough CW, Gong Y, et al. Association of kcnj1 variation with change in fasting glucose and new onset diabetes during hctz treatment. Pharmacogenomics J 2012; [Epub ahead of print] doi: 10.1038/tpj.2012.34.
11. Nichols GA, Hillier TA, Brown JB. Normal fasting plasma glucose and risk of type 2 diabetes diagnosis. Am J Med 2008;121: 519-24.
12. Tirosh A, Shai I, Tekes-Manova D, et al. Normal fasting plasma glucose levels and type 2 diabetes in young men. N Engl J Med 2005;353: 1454-62.
13. Wang TJ, Larson MG, Vasan RS, et al. Metabolite profiles and the risk of developing diabetes. Nat Med 2011;17: 448-53.
14. Cooper-DeHoff RM, Hou W, Baillie R, et al. Pharmacometabolomics reveals a novel signature for predicting beta blocker associated impaired fasting glucose. Circulation 2012;126: A11088.
15. Scott RA, Lagou V, Welch RP, et al. Consortium DGRaM-aD. Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways. Nat Genet 2012;44: 991-1005.
16. Dupuis J, Langenberg C, Prokopenko I, et al. Consortium AHoboP, investigators M. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet 2010;42: 105-16.
17. Johnson JA, Boerwinkle E, Zineh I, et al. Pharmacogenomics of antihypertensive drugs: rationale and design of the pharmacogenomic evaluation of antihypertensive responses (PEAR) study. Am Heart J 2009;157: 442-9.
18. Wallace TM, Levy JC, Matthews DR. Use and abuse of homa modeling. Diabetes Care 2004;27: 1487-95.
19. Keating BJ, Tischfield S, Murray SS, et al. Concept, design and implementation of a cardiovascular gene-centric 50 k snp array for large-scale genomic association studies. PLoS ONE 2008;3:e3583.
20. Purcell S, Neale B, Todd-Brown K, et al. Plink: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007;81: 559-75.
21. Daly AK. Genome-wide association studies in pharmacogenomics. Nat Rev Genet 2010;11: 241-6.
22. Gong Y, McDonough CW, Wang Z, et al. Hypertension susceptibility loci and blood pressure response to antihypertensives: results from the pharmacogenomic evaluation of antihypertensive responses study. Circ Cardiovasc Genet 2012;5: 686-91.
23. Del-Aguila JL, Beitelshees AL, Cooper-Dehoff RM, et al. Genome- wide association analyses suggest nell1 influences adverse metabolic response to hctz in African Americans. Pharmacogenomics J 2013;[Epub ahead of print] doi: 10.1038/tpj.2013.3.
24. Turner ST, Bailey KR, Schwartz GL, Chapman AB, Chai HS, Boerwinkle E. Genomic association analysis identifies multiple loci influencing antihypertensive response to an angiotensin ii receptor blocker. Hypertension 2012;59: 1204-11.
25. Song KH, Li T, Chiang JY. A prospero-related homeodomain protein is a novel co-regulator of hepatocyte nuclear factor 4alpha that regulates the cholesterol 7alpha-hydroxylase gene. J Biol Chem 2006;281: 10081-8.
26. Yamagata K, Furuta H, Oda N, et al. Mutations in the hepatocyte nuclear factor-4alpha gene in maturity-onset diabetes of the young (mody1). Nature 1996;384: 458-60.
27. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2002;288: 2981-97.